4qt5: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
==Crystal Structure of 3BD10: A Monoclonal Antibody against the TSH Receptor==
==Crystal Structure of 3BD10: A Monoclonal Antibody against the TSH Receptor==
<StructureSection load='4qt5' size='340' side='right' caption='[[4qt5]], [[Resolution|resolution]] 2.50&Aring;' scene=''>
<StructureSection load='4qt5' size='340' side='right' caption='[[4qt5]], [[Resolution|resolution]] 2.50&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[4qt5]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4QT5 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4QT5 FirstGlance]. <br>
<table><tr><td colspan='2'>[[4qt5]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4QT5 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4QT5 FirstGlance]. <br>
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4qt5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4qt5 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4qt5 RCSB], [http://www.ebi.ac.uk/pdbsum/4qt5 PDBsum]</span></td></tr>
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4qt5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4qt5 OCA], [http://pdbe.org/4qt5 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4qt5 RCSB], [http://www.ebi.ac.uk/pdbsum/4qt5 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4qt5 ProSAT]</span></td></tr>
</table>
</table>
<div style="background-color:#fffaf0;">
<div style="background-color:#fffaf0;">
Line 13: Line 14:
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
</div>
<div class="pdbe-citations 4qt5" style="background-color:#fffaf0;"></div>
== References ==
== References ==
<references/>
<references/>

Revision as of 20:09, 4 January 2017

Crystal Structure of 3BD10: A Monoclonal Antibody against the TSH ReceptorCrystal Structure of 3BD10: A Monoclonal Antibody against the TSH Receptor

Structural highlights

4qt5 is a 4 chain structure. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Publication Abstract from PubMed

The TSH receptor (TSHR) A-subunit is more effective than the holoreceptor in inducing thyroid-stimulating antibodies (TSAb) that cause Graves' disease. A puzzling phenomenon is that 2 recombinant, eukaryotic forms of A-subunits (residues 22-289), termed active and inactive, are recognized mutually exclusively by pathogenic TSAb and mouse monoclonal antibody 3BD10, respectively. Understanding the structural difference between these TSHR A-subunit forms could provide insight into Graves' disease pathogenesis. The 3-dimensional structure of the active A-subunit (in complex with a human TSAb Fab, M22) is known, but the structural difference with inactive A-subunits is unknown. We solved the 3BD10 Fab 3-dimensional crystal structure. Guided by prior knowledge of a portion of its epitope, 3BD10 docked in silico with the known active TSHR-289 monomeric structure. Because both TSAb and 3BD10 recognize the active TSHR A-subunit monomer, this form of the molecule can be excluded as the basis for the active-inactive dichotomy, suggesting, instead a role for A-subunit quaternary structure. Indeed, in silico analysis revealed that M22, but not 3BD10, bound to a TSHR-289 trimer. In contrast, 3BD10, but not M22, bound to a TSHR-289 dimer. The validity of these models is supported experimentally by the temperature-dependent balance between active and inactive TSHR-289. In summary, we provide evidence for a structural basis to explain the conformational heterogeneity of TSHR A-subunits (TSHR-289). The pathophysiologic importance of these findings is that affinity maturation of pathogenic TSAb in Graves' disease is likely to involve a trimer of the shed TSHR A-subunit.

Crystal structure of a TSH receptor monoclonal antibody: insight into Graves' disease pathogenesis.,Chen CR, Hubbard PA, Salazar LM, McLachlan SM, Murali R, Rapoport B Mol Endocrinol. 2015 Jan;29(1):99-107. doi: 10.1210/me.2014-1257. PMID:25419797[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

References

  1. Chen CR, Hubbard PA, Salazar LM, McLachlan SM, Murali R, Rapoport B. Crystal structure of a TSH receptor monoclonal antibody: insight into Graves' disease pathogenesis. Mol Endocrinol. 2015 Jan;29(1):99-107. doi: 10.1210/me.2014-1257. PMID:25419797 doi:http://dx.doi.org/10.1210/me.2014-1257

4qt5, resolution 2.50Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA